Researchers found that the glycan RPTP zeta S3L binds to microglial CD33 receptors in Alzheimer’s patients, suggesting a new target for diagnostics and treatment.
In a bit of “reverse engineering” research using brain tissues from five people who died with Alzheimer’s disease, Johns Hopkins Medicine researchers say they have discovered that a special sugar molecule could play an important role in the development of Alzheimer’s disease. If the finding is confirmed by further research, the molecule, known as a glycan, could serve as a new target for early diagnostic tests, treatments, and perhaps even prevention of Alzheimer’s disease, say the scientists.
The study was published recently in the Journal of Biological Chemistry.
In the United States, Alzheimer’s disease is the most common form of dementia. Affecting an estimated 5.8 million Americans, the progressive disorder occurs when nerve cells in the brain die from the buildup of harmful forms of proteins called amyloid and tau.
The Role of Microglia and CD33 in Alzheimer’s
Cleaning up these disease-causing forms of amyloid and tau is the job of the brain’s immune cells, called microglia. Earlier research discovered that Alzheimer’s disease is more likely to occur when cleanup is impaired. In some people, this is caused by an overabundance of a receptor on the microglia cells, called CD33.
“Receptors are not active on their own. Something needs to connect with them to block microglia from cleaning up these toxic proteins in the brain, says Ronald Schnaar, Ph.D., the John Jacob Abel Professor of Pharmacology at the Johns Hopkins University School of Medicine and director of the laboratory that led the study.
Past studies by the researchers showed that for CD33, these “connector” molecules are special sugars. Known to scientists as glycans, these molecules are ferried around the cell by specialized proteins that help them find their appropriate receptors. The protein-glycan combination is called a glycoprotein.
In a bid to find out which specific glycoprotein connects with CD33, Schnaar’s research team obtained brain tissue from five people who died of Alzheimer’s disease and from five people who died from other causes from the Johns Hopkins Alzheimer’s Disease Research Center. Among the many thousands of glycoproteins they gathered from the brain tissues, only one connected to CD33.
To identify this mystery glycoprotein, the researchers first needed to separate it from the other brain glycoproteins. Since it was the only one in the brain that attached itself to CD33, they used this feature to “catch” it and separate it.
Deconstructing the Glycan: Sialylated Keratan Sulfate
Glycans are made up of various sugar building blocks that influence the molecule’s interactions. Such sugars can be identified by their component parts. The researchers used chemical tools to deconstruct the glycan step by step, laying out the identity and order of its building blocks. The researchers identified the glycan portion of the glycoprotein as sialylated keratan sulfate.
Then, the researchers determined the protein component’s identity by taking its “fingerprint” using mass spectroscopy, which identifies protein building blocks. By comparing the molecular makeup of the protein with a database of known protein structures, the research team was able to conclude the protein portion of the glycoprotein was receptor tyrosine phosphatase (RPTP) zeta.
The researchers named the combined glycoprotein structure RPTP zeta S3L.
The group had previously found the same glycan “signature” on a protein that controls allergic responses in the airway, and that disrupting the glycan dampened allergic responses in mice.
“We suspect the glycan signature carried on RPTP zeta may have a similar role in deactivating microglia through CD33,” says Anabel Gonzalez-Gil Alvarenga, Ph.D., postdoctoral fellow in the Schnaar laboratory and first author of the study.
Increased Levels of RPTP Zeta S3L in Alzheimer’s Patients
Further experiments showed that the brain tissue of the five people who died with Alzheimer’s disease had more than twice as much RPTP zeta S3L as the donors who did not have the disease. This implies that this glycoprotein may be connecting with more CD33 receptors than a healthy brain, limiting the brain’s ability to clean up harmful proteins.
“Identifying this unique glycoprotein provides a step toward finding new drug targets and potentially early diagnostics for Alzheimer’s disease,” says Gonzalez-Gil.
Next, the researchers plan to further study RPTP zeta S3L’s structure to determine how its attached glycans give the glycoprotein its unique ability to interact with CD33.
Reference: “Human brain sialoglycan ligand for CD33, a microglial inhibitory Siglec implicated in Alzheimer’s disease” by Anabel Gonzalez-Gil, Ryan N. Porell, Steve M. Fernandes, Eila Maenpaa, T. August Li, Tong Li, Philip C. Wong, Kazuhiro Aoki, Michael Tiemeyer, Zaikuan J. Yu, Benjamin C. Orsburn, Namandjé N. Bumpus, Russell T. Matthews and Ronald L. Schnaar, 19 April 2022, Journal of Biological Chemistry.
DOI: 10.1016/j.jbc.2022.101960
Other researchers involved in this study include Ryan Porell, Steve Fernandes, Eila Maenpaa, T. August Li, Tong Li, Philip Wong, Zaikuan Yu, Benjamin Orsburn and Namandjé Bumpus of the Johns Hopkins University School of Medicine; Kazuhiro Aoki and Michael Tiemeyer of the University of Georgia and Russell Matthew of the State University of New York Upstate Medical University.
This research was supported by the National Institute on Aging (AG062342 and AG068089), the National Heart, Lung, and Blood Institute (K12-HL141952) and the National Institute of General Medical Sciences (T32-GM008763,T32-GM080189). Human brain tissues were provided by the Johns Hopkins Alzheimer’s Disease Research Center.
Never miss a breakthrough: Join the SciTechDaily newsletter.
Follow us on Google and Google News.